Our team includes world-class scientists, chemists, engineers, operators and more -- all working together to drive our important work forward. Learn more: Amneal.com
Amneal Pharmaceuticals
Pharmaceutical Manufacturing
Bridgewater, New Jersey 255,200 followers
We make healthy possible.
About us
Amneal (NASDAQ: AMRX) is rapidly becoming one of the most dynamic, purpose-driven pharmaceutical companies delivering more affordable access to essential medicines. Our family delivers for yours through a robust U.S. generics business, a growing branded business and deepening portfolios in injectables, biosimilars and select international markets. We’ve bolstered our world-class scientific rigor, production capabilities and commercial infrastructure. And we invest substantially in our people through leadership development and employee well-being programs – all so we can deliver even more value. We are Amneal and We make healthy possible. Content is for informational purposes only and 3rd party content does not reflect Amneal’s opinions. Amneal has the right to remove comments that violate another’s copyright or intellectual property, mention an Amneal product, use profanity or are defamatory, promote and solicit for third-party sites, initiatives, or products, or are factually inaccurate or misleading or spam. Amneal recommends that you consult with your healthcare provider regarding personal health matters. To report a product complaint or adverse event related to an Amneal product, contact Drug Safety at 877-835-5472, option 3 or drugsafety@amneal.com. If you are currently experiencing a life-threatening event, please immediately contact 911.
- Website
-
http://www.amneal.com
External link for Amneal Pharmaceuticals
- Industry
- Pharmaceutical Manufacturing
- Company size
- 5,001-10,000 employees
- Headquarters
- Bridgewater, New Jersey
- Type
- Public Company
- Founded
- 2002
Locations
-
Primary
Get directions
400 Crossing Boulevard
Bridgewater, New Jersey 08807, US
Employees at Amneal Pharmaceuticals
Updates
-
Together, we can do more to improve health. That’s a powerful reason to come to work. We’re also focused on rapidly growing our capabilities, our product portfolios and our people – all to increase the number of lives we can touch. Want to join our team? Check out: https://lnkd.in/gqi3Zyen
-
-
Our Co-Founder and & Co-CEO Chirag Patel says it best! Learn more: Amneal.com
-
-
We announced the submission of a Biologics License Application (BLA) to the U.S. FDA for a proposed biosimilar to XOLAIR® (omalizumab), developed by Kashiv BioSciences, LLC. Learn more: https://lnkd.in/eWqXEKNp XOLAIR® (omalizumab) is a registered trademark of Novartis AG
-
Since our founding in 2002, we have methodically diversified beyond generics to build a broad and differentiated portfolio of branded and complex products. We’re pleased to share that the U.S. FDA has approved our Abbreviated New Drug Application (ANDA) for bimatoprost ophthalmic solution 0.01%, the generic equivalent of LUMIGAN® 0.01% (design is a trademark of Allergan, Inc., an AbbVie company). Learn more: https://lnkd.in/gEsQMEWE
-
When our people grow, Amneal grows. Learn more: Amneal.com/careers
-
We’ve evolved from generics to innovative and complex medicines, and we are entering our next phase of growth focused on reaching more patients. *A majority of our projects in the GLP-1 / Peptides category are in development and not yet approved **Amneal has three reportable business segments: 1) Affordable Medicines (includes retail generics, injectables, biosimilars & international revenue), 2) Specialty and 3) AvKARE (includes distribution, government label and institutional revenue).
-
-
We’ve received U.S. FDA approval of Amneal’s sodium oxybate oral solution 500 mg/mL Abbreviated New Drug Application (ANDA) which references Jazz Pharmaceuticals’ Xyrem®. Amneal had previously been distributing an authorized generic of sodium oxybate oral solution in limited quantities. This approval expands our Affordable Medicines portfolio and broadens patient access. Learn more: https://lnkd.in/g3PK9Trx Xyrem® is a registered trademark of Jazz Pharmaceuticals, Inc.
-
-
We’ve received U.S. FDA approval of risperidone extended-release injectable suspension 12.5 mg/vial, 25 mg/vial, 37.5 mg/vial and 50 mg/vial, which references Janssen’s Risperdal Consta®. Our product is eligible for 180-day exclusivity under the FDA’s Competitive Generic Therapy (CGT) designation, and we expect to launch in the fourth quarter of 2025.This milestone reflects our strong R&D and manufacturing expertise, and paves the way for future innovation in microsphere-based long-acting injectables. Learn more: https://lnkd.in/ehwsbQrr *Risperdal Consta® is a registered trademark of Janssen